Berenberg raised the firm’s price target on Novartis to CHF 77 from CHF 74 and keeps a Hold rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis meets all tender offer conditions to acquire MorphoSys
- Novartis to present data from Phase 3 ASC4FIRST study at ASCO and EHA
- H.C. Wainwright sees Actinium as buyout candidate after Mariana deal
- Genmab reports Q1 revenue increased 46% vs. last year
- FTC expands patent listing challenges for drugs